| Identification | Back Directory | [Name]
JKC-301 | [CAS]
136553-96-3 | [Synonyms]
JKC-301
CYCLO(-D-ASP-PRO-D-ILE-LEU-D-TRP)
Cyclo(D-α-aspartyl-L-prolyl-D-isoleucyl-L-leucyl-D-tryptophyl)
JKC 301 (CYCLO-[D-ASP-PRO-D-LLE-LEU-D-TR P]), SYNTHETIC, >99% PURITY | [Molecular Formula]
C32H44N6O7 | [MDL Number]
MFCD00214626 | [MOL File]
136553-96-3.mol | [Molecular Weight]
624.73 |
| Chemical Properties | Back Directory | [Boiling point ]
1052.2±65.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
-15°C | [pka]
4.04±0.10(Predicted) | [Sequence]
Cyclo({d-Asp}-Pro-{d-Ile}-Leu-{d-Trp}) |
| Hazard Information | Back Directory | [Uses]
JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking[1][2]. | [References]
[1] Tanus-Santos JE, Sampaio RC, Hyslop S, Franchini KG, Moreno H Jr. Endothelin ET(A) receptor antagonism attenuates the pressor effects of nicotine in rats. Eur J Pharmacol. 2000 May 12;396(1):33-7. DOI:10.1016/s0014-2999(00)00194-1
[2] Ngoka LC, et al. Location of alkali metal binding sites in endothelin A selective receptor antagonists, cyclo(D-Trp-D-Asp-Pro-D-Val-Leu) and cyclo(D-Trp-D-Asp-Pro-D-Ile-Leu), from multistep collisionally activated decompositions. J Mass Spectrom. 2000 Feb;35(2):265-76. DOI:10.1002/(SICI)1096-9888(200002)35:2<265::AID-JMS946>3.0.CO;2-# |
|
| Company Name: |
Nextpeptide Inc
|
| Telephone: |
+86-0571-81612335 +8613336028439 |
| Website: |
http://www.nextpeptide.com/ |
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|